The Governance Roots
of the US Healthcare Crisis
How much of the US healthcare crisis is a problem of governance?
The United States spends more on healthcare than any other country, yet Americans face some of the world’s highest prices, narrow choices and uneven quality. The usual debate is about money. Our first academic symposium asked who gets to decide, what they are rewarded for, and how much say patients really have.
10 papers · 2 days · economics, philosophy, law & policy
The Papers
01
The Malleability of Treatment Choice in US Cancer Care: Identification and Implications
Prostate cancer treatments can differ fortyfold in cost with little difference in survival, yet treatment jumps at a PSA reading of exactly 20. Round numbers, not patients, are deciding. Sharing savings with patients and AI outcome predictions could hand the choice back.
Forthcoming
02
Options for State-Level Health Policy, Insurance, and Delivery Innovation
ACA rules have pushed up premiums and narrowed networks. US territories are already exempt, so states could let residents buy territory-regulated plans, saving 60–88% on premiums, while guaranteed renewability protects people who fall ill.
Forthcoming
03
Promoting Individual Choice and Agency in U.S. Healthcare
Family coverage now costs around $29,000 a year, and patients who have met their deductible have almost no reason to compare prices. Employers are losing faith that they can fix costs, so real consumer choice must be built into existing programs.
Forthcoming
04
Consumer Sovereignty, Entrepreneurial Discovery, and Direct Primary Care
Letting HSAs cover direct primary care is a real step forward, but its rules steer innovation towards tax-compliant models. Congress can only legislate around models it can see. The fix: let all health spending come from pre-tax income.
Forthcoming
05
The Duty to Explain in Healthcare: Accuracy, Authority, and Fiduciary Trust
Making a decision explainable can cost accuracy. But opaque AI adds a second uncertainty: whether its success rate even applies to you. Choosing a slightly less accurate model you can understand can be rational, so that choice belongs in the consent conversation between patient and clinician.
Forthcoming
06
Right Diagnosis, Wrong Cure
The US accounts for around three-quarters of patented drug revenue, funding cures the world enjoys. Pegging prices to foreign ones would shrink that pipeline. Trade leverage works better: the UK now pays 25% more for US medicines in return for tariff exemptions.
Forthcoming
07
The Knowledge Problems of Neo-Brandeisian Anti-trust: The Case of US Hospital Mergers
The antitrust debate is about knowledge, not definitions. Regulators cannot reliably tell whether a hospital merger will harm patients, and past interventions may have fuelled the very concentration they targeted. The consumer welfare standard’s simple rules ask far less of them.
08
The Transatlantic Feedback Loop: How Reference Pricing Models Could Cause Manufacturers to Shift Away from a U.S. First Global Launch Strategy
Projected savings from Medicare’s reference pricing models have collapsed from about $12 billion to $440 million. Meanwhile, drugmakers are already delaying launches in markets like Denmark and the UK. The fix lies in domestic reform, not imported foreign prices.
Forthcoming
09
Medicare Payment Reform Through Direct Cash Transfers
Medicare lets Washington decide how care is paid for, though no single payment model suits every patient. A risk-adjusted cash transfer, which enrollees direct to the plan they choose and whose surplus they keep, would let payment models compete on equal terms.
Forthcoming
10
Insulin Copays and Use After the Medicare Cap in Type 2 Diabetes: A Matched Cohort Study of Medicare Advantage Beneficiaries
The $35 insulin copay cap mostly didn’t bind: average copays were already lower. Where it did apply, it worked as a cash transfer of about $99 a year rather than improving adherence or health, because patients need insulin whatever it costs.
Forthcoming
Day by Day
Day 1 Recap: The Governance Roots of the US Healthcare Crisis
How seemingly minor rules, from a PSA reading of 20 to fee caps and insurance mandates, end up deciding what happens to patients, and what it would take to put them back in charge.
Day 2 Recap: The Governance Roots of the US Healthcare Crisis
No regulator can know what every patient needs. Day two tested that idea against the insulin copay cap, hospital mergers and drug pricing, and made the case for competition and choice.
Videos
Symposium overview
Op-eds
29 October 2026
Drawing on his symposium paper, Emil argues that the evidence that bigger hospitals mean higher prices and worse care is more mixed than the FTC suggests.